Previous close | 0.0620 |
Open | 0.0640 |
Bid | 0.0740 x N/A |
Ask | 0.0800 x N/A |
Day's range | 0.0640 - 0.0790 |
52-week range | 0.0100 - 0.1300 |
Volume | |
Avg. volume | 4,785,339 |
Market cap | N/A |
Beta (5Y monthly) | 0.68 |
PE ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
Lumos Diagnostics Holdings ( ASX:LDX ) Full Year 2023 Results Key Financial Results Revenue: US$10.5m (down 9.4% from...
Lumos Diagnostics (ASX: LDX), ("Lumos" or the "Company") a leader in rapid, point-of-care (POC) diagnostic technologies, is pleased to announce that it has received clearance from the US Food and Drug Administration (FDA) to market its FebriDx® rapid, point-of-care test in the United States.